Revance TherapeuticsRVNC
RVNC
About: Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Employees: 597
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
97% more capital invested
Capital invested by funds: $219M [Q2] → $431M (+$212M) [Q3]
61% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 44
15% more funds holding
Funds holding: 172 [Q2] → 198 (+26) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
1.89% less ownership
Funds ownership: 81.68% [Q2] → 79.79% (-1.89%) [Q3]
17% less call options, than puts
Call options by funds: $4.42M | Put options by funds: $5.33M
28% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 54
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
17%
downside
Avg. target
$4.23
17%
upside
High target
$6.60
82%
upside
3 analyst ratings
0 positive
0%
3 neutral
100%
0 negative
0%
Barclays Balaji Prasad 44% 1-year accuracy 18 / 41 met price target | 17%downside $3 | Equal-Weight Maintained | 23 Dec 2024 |
Mizuho Vamil Divan 40% 1-year accuracy 8 / 20 met price target | 15%downside $3.10 | Neutral Maintained | 10 Dec 2024 |
HC Wainwright & Co. Douglas Tsao 35% 1-year accuracy 61 / 175 met price target | 82%upside $6.60 | Neutral Reiterated | 8 Nov 2024 |
Financial journalist opinion
Based on 210 articles about RVNC published over the past 30 days
Neutral
Accesswire
10 hours ago
Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126489&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
16 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
NEW YORK CITY, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Neutral
Accesswire
1 day ago
Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – RVNC
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126430&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
1 day ago
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or “the Company”) (NASDAQ: RVNC) and certain of its officers.
Neutral
Accesswire
1 day ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Revance Therapeutics Inc
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
Neutral
Accesswire
1 day ago
Revance Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights – RVNC
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126375&wire=1 or contact Joseph E. Levi, Esq.
Neutral
PRNewsWire
1 day ago
Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES , Jan. 31, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) have opportunity to lead the securities fraud class action lawsuit.
Neutral
Accesswire
1 day ago
Shareholders That Lost Money on Revance Therapeutics, Inc. (RVNC) Should Contact Levi & Korsinsky About Pending Class Action - RVNC
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126246&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
1 day ago
Revance Therapeutics, Inc. Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Losses Should Contact the Law Firm for More Information
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Revance Therapeutics, Inc. (NASDAQ:RVNC). The lawsuit seeks to recover losses on behalf of investors who acquired securities between February 29, 2024 and December 6, 2024. Investors have until March 4, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Neutral
PRNewsWire
1 day ago
Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline
Crown offer of $3.65 per share is the only offer available to Revance stockholders Crown offer unanimously approved by the Revance Board of Directors Teoxane withdraws its previous proposal, says it will tender its 6.2% stake in Revance into Crown tender Tender offer expires at one minute past 11:59 p.m., Eastern Time, on February 4, 2025 JOHNSON CITY, Tenn.
Charts implemented using Lightweight Charts™